Cormorant Asset Management, LP - Sep 15, 2023 Form 4 Insider Report for Ambrx Biopharma Inc. (AMAM)

Role
10%+ Owner
Signature
/s/ CORMORANT ASSET MANAGEMENT, LP By: Cormorant Asset Management GP, LLC, its General Partner
Stock symbol
AMAM
Transactions as of
Sep 15, 2023
Transactions value $
$19,625,601
Form type
4
Date filed
9/19/2023, 04:49 PM
Previous filing
Jul 24, 2023
Next filing
Oct 25, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMAM Ordinary Shares Purchase $12.7M +1.4M +2.08% $9.05 68.7M Sep 15, 2023 See Footnotes F1, F2, F3
transaction AMAM Ordinary Shares Purchase $6.94M +751K +1.09% $9.24 69.5M Sep 18, 2023 See Footnotes F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the weighted average sale price of American Depository Shares ("ADS") purchased in a series of open market transactions on the transaction date at prices ranging from $9.00 to $9.30 per ADS. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ADS purchased at each price. All of these ADS were purchased by the Master Fund (as defined below).
F2 Information reported herein relates to ordinary shares represented by ADS owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund III, LP ("Fund III"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund and Fund III. Cormorant Global Healthcare GP, LLC ("GP LLC") and Cormorant Private Healthcare GP III, LLC ("GP III") serve as General Partner of the Master Fund and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP III. Each of the Reporting Persons disclaims beneficial ownership of the ordinary shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
F3 Represents (i) 51,172,870 ordinary shares beneficially owned by the Master Fund and (ii) 17,541,720 ordinary shares beneficially owned by Fund III.
F4 Represents (i) 51,924,103 ordinary shares beneficially owned by the Master Fund and (ii) 17,541,720 ordinary shares beneficially owned by Fund III.